Our experience

Нour specialists have considerable experience in all common nosologies, and also have special competence in conducting research of early phases. Use the filter to select the categories of research and services you are interested in.

Services






Year





INNCodeАТСServicesYear
Teriflunomide L04AA Selective Immunosuppressive Agents Bioequivalence CT Present
Sorafenib L01XE Protein kinase inhibitors Bioequivalence CT Present
Abacavir J05AF Nucleoside reverse transcriptase inhibitors Bringing dossier into the EEU complience Present
Bortezomib L01XX Ингибиторы протеинкиназы Bringing dossier into the EEU complience Present
Bromhexine + Guaifenesin + Salbutamol R05C Expectorants,Excl Combinations With Cough Suppr. Bringing dossier into the EEU complience Present
Darunavir J05AE HIV-proteinase inhibitors Bringing dossier into the EEU complience Present
Metronidazole A01AB Antiinfectives For Local Oral Treatment Bringing dossier into the EEU complience Present
Oxaliplatin L01XA Platinum Compounds Bringing dossier into the EEU complience Present
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT Present
Etoricoxib M01AH Coxibs Bioequivalence CT Present
Interferon y L03AB Interferons Phase III CT Present
Сlindamycin + Adapalene D01A Antifungals for topical use Bringing dossier into the EEU complience Present
Ketoconazole + Pyrithione zinc D01A Antifungals for topical use Bringing dossier into the EEU complience Present
Desloratadine R06AX Other Antihistamines for systemic use Marketing Authorization Present
Tibolone G03CX Other estrogens Marketing Authorization Present
Acetylcysteine R05CB Mucolytics Marketing Authorization Present
Decitabine L01BC Pyrimidine Analogues Marketing Authorization Present
Glucoseminyl muramildipeptide L03AX Other Immunostimulating Agents Bringing dossier into the EEU complience Present
Imipenem + Cilastatin J01DH Carbapenems Marketing Authorization Present
Atosiban G02CX Gynecologicals, other Marketing Authorization Present
Iloprost B01AC Platelet Aggregation Inhibitors Excl. Marketing Authorization Present
Nimodipine C08CA Dihydropyridine Derivatives Marketing Authorization Present
Aminoacids for parenteral nutrition A16AA Amino Acids and Derivatives Marketing Authorization Present
Dexmedetomidine N05C Hypnotics and Sedatives Marketing Authorization Present
Teriflunomide L04AA Selective Immunosuppressive Agents Marketing Authorization Present
Nitisinone A16AX Various Alimentary Tract and Metabolism Products Marketing Authorization Present
Biapenem J01D Third-generation cephalosporins Marketing Authorization Present
Paclitaxel L01CD Taxanes Marketing Authorization Present
Сolistimethate sodium J01XB Polymyxins Marketing Authorization Present
Cinacalcet H05BX Other anti-parathyroid agents Marketing Authorization Present
Gadodiamide V08CA Paramagnetic Contrast Media Marketing Authorization Present
Dantrolene M03CA Dantrolene and Derivatives Marketing Authorization Present
Cefuroxime J01RA Combinations Of Antibacterials Marketing Authorization Present
Ertapenem J01DH Carbapenems Marketing Authorization Present
Bromhexine + Guaifenesin + Salbutamol R05C Expectorants,Excl Combinations With Cough Suppr. Marketing Authorization Present
Vancomycin J01XA Glycopeptide Antibacterials Marketing Authorization Present
Tiepenem J01DH Carbapenems Marketing Authorization Present
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization Present
Aminoacids for parenteral nutrition A16AA Amino Acids and Derivatives Marketing Authorization Present
Clotrimazole D01AC Imidazole Derivatives Bringing dossier into the EEU complience Present
Adapalenum + Clindamycinum D10AD Retinoids for topical use In Acne Bringing dossier into the EEU complience Present
Combined herb drug A01AD Other Agents For Local Oral Treatment Bioequivalence CT Present
Hydrochlorothiazidum + Telmisartan C09DA Angiotensin II Antagonists and Diuretics Bioequivalence CT Present
Indapamid + Perindopril + Rosuvastatin C10BX HMG CoA reductase inhibitors, other combinations Bioequivalence CT Present
Dabigatrani etexilas B01AA Vitamin K Antagonists Bioequivalence CT Present
Amlodipinum + Indapamidum + Perindoprilum C09BX Ингибиторы АПФ, другие комбинации Bioequivalence CT Present
Apixaban B01AF Other Antithrombotic Agents Bioequivalence CT Present
Dapagliflozin A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors Bioequivalence CT Present
Tilorone J05AX Other Antivirals Bioequivalence CT Present
Darunavir J05AE HIV-proteinase inhibitors Bioequivalence CT Present
Etravirin J05AG Ненуклеозиды - ингибиторы обратной транскриптазы Bioequivalence CT Present
Abacavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT Present
Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT Present
Posaconazole J02AC Triazole Derivatives Bioequivalence CT 2019-2021
Teriflunomide L04AA Selective Immunosuppressive Agents Bioequivalence CT 2019-2021
Etravirin J05AG Ненуклеозиды - ингибиторы обратной транскриптазы Bioequivalence CT 2019-2021
Cinacalcet H05BX Other anti-parathyroid agents Bioequivalence CT 2019-2021
Sunitinib L01XE Protein kinase inhibitors Bioequivalence CT 2019-2021
Nitisinone A16AX Various Alimentary Tract and Metabolism Products Bioequivalence CT 2019-2021
Nilotinib L01XE Protein kinase inhibitors Bioequivalence CT 2019-2021
Lenalidomide L04AX Other Immunosuppressive Agents Bioequivalence CT 2019-2021
Desloratadine R06AX Other Antihistamines for systemic use Bioequivalence CT 2019-2021
Dasatinib L01XE Protein kinase inhibitors Bioequivalence CT 2019-2021
Acetylcysteine R05CB Mucolytics Bioequivalence CT 2019-2021
Gefitinib L01XX Other Antineoplastic Agents Bioequivalence CT 2019-2021
Chlorprothixen N05AF Thioxanthene Derivatives Bioequivalence CT 2019-2021
Etoricoxib M01AH Coxibs Bioequivalence CT 2019-2021
Vinorelbine L01CA Vinca alkaloids and analogues Marketing Authorization 2019-2021
Melatonin + Glycine N06BX Other Psychostimulants and Nootropics Phase III CT 2019-2021
Rabeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2019-2021
Trimebutine A03AA Synt Anticholin,Esters With Tertiary Amino Group Bioequivalence CT 2019-2021
Tolperisone M02AX Other Topical Products For Joint and Muscular Pain Bioequivalence CT 2019-2021
Mebeverine A03AA Synt Anticholin,Esters With Tertiary Amino Group Bioequivalence CT 2019-2021
Cefoperazone J01DD Third-generation cephalosporins Marketing Authorization 2019-2021
Cefoxitin J01DC Second-generation cephalosporins Marketing Authorization 2019-2021
Ketoanalogues of aminoacids V06DD Amino Acids, Incl Combinations With Polypeptides Marketing Authorization 2019-2021
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Marketing Authorization 2019-2021
Oseltamyvir J05AH Neuraminidase inhibitors Bringing dossier into the EEU complience 2019-2021
Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid N02B Other Analgesics and Antipyretics Marketing Authorization 2019-2021
Paracetamol + Phenylephrine + Pheniramine + Caffeine N02B Other Analgesics and Antipyretics Marketing Authorization 2019-2021
Saquinavir J05AE HIV-proteinase inhibitors Marketing Authorization 2019-2021
Ademetionin A16AA Amino Acids and Derivatives Marketing Authorization 2019-2021
Ambroxol + Salbutamol + Guaifenesin R05C Expectorants,Excl Combinations With Cough Suppr. Marketing Authorization 2019-2021
Amoxicillin + Sulbactam J01CG Beta-Lactamase Inhibitors Marketing Authorization 2019-2021
Ampicillin + Sulbactam J01CR Comb Of Penicillins, Incl. Beta-Lactamase Inhib. Marketing Authorization 2019-2021
Amylmetacresol + Dichlorobenzyl alcohol R02AA Antiseptics Marketing Authorization 2019-2021
Anagrelide L01XX Other Antineoplastic Agents Marketing Authorization 2019-2021
Aripiprazole N05AX Other Antipsychotics Bioequivalence CT 2019-2021
Aripiprazole N05AX Other Antipsychotics Marketing Authorization 2019-2021
Aztreonam J01DF Monobactams Marketing Authorization 2019-2021
Caffeine + Paracetamol + Phenylephrine + Chlorphenamine N02B Other Analgesics and Antipyretics Marketing Authorization 2019-2021
Cefepime J01DE Fourth-generation cephalosporins Marketing Authorization 2019-2021
Cefoperazone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization 2019-2021
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Marketing Authorization 2019-2021
Vildagliptin A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors Bioequivalence CT 2019-2021
Vildagliptin + Metformin A10BD Biguanides and Sulfonamides In Combination Bioequivalence CT 2019-2021
Clotrimazole D01A Antifungals for topical use Marketing Authorization 2019-2021
Cyproterone G03HA Antiandrogens, Plain Preparations Marketing Authorization 2019-2021
Cytisine N07BA Antismoking Agents Marketing Authorization 2019-2021
Dexmedetomidine N05CM Other Hypnotics and Sedatives Marketing Authorization 2019-2021
Dimetinden R06A Antihistamines for systemic use Marketing Authorization 2019-2021
Diosmin + Hesperidin C05CA Bioflavonoids Marketing Authorization 2019-2021
Docetaxel L01CD Taxanes Marketing Authorization 2019-2021
Domperidone A03FA Propulsives Marketing Authorization 2019-2021
Desogestrel + Ethinylestradiol G03AA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2019-2021
Donepezil N06DA Cholinesterase inhibitors Bioequivalence CT 2019-2021
Fluvoxamine N06AB Serotonin Reuptake Inhibitors Selective Marketing Authorization 2019-2021
Fosfomycin J01XX Other Antibacterials Marketing Authorization 2019-2021
Gemcitabine L01BC Pyrimidine Analogues Marketing Authorization 2019-2021
Ibuprofen M01AE Propionic Acid Derivatives Marketing Authorization 2019-2021
Ibuprofen + Paracetamol M01AE Propionic Acid Derivatives Marketing Authorization 2019-2021
Iodixanol V08A X-Ray Contrast Media, Iodinated Marketing Authorization 2019-2021
Irinotecan L01XX Ингибиторы протеинкиназы Marketing Authorization 2019-2021
Josamycin J01FA Macrolides Marketing Authorization 2019-2021
Lysocime + Pyridoxine R02AA Antiseptics Marketing Authorization 2019-2021
Metronidazole + Chlorhexidine A01AB Antiinfectives For Local Oral Treatment Marketing Authorization 2019-2021
Montelukast R03DC Leukotriene receptor antagonists Marketing Authorization 2019-2021
Naftifine D01A Antifungals for topical use Marketing Authorization 2019-2021
Natamycin A07AA Antibiotics Marketing Authorization 2019-2021
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Marketing Authorization 2019-2021
Olmesartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2019-2021
Omeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2019-2021
Ornidazole J01XD Imidazole Derivatives Marketing Authorization 2019-2021
Ornidazole + Ciprofloxacin J01RA Combinations Of Antibacterials Marketing Authorization 2019-2021
Pancreatin A09AA Enzyme Preparations Marketing Authorization 2019-2021
Phosphazide J05AF Nucleoside reverse transcriptase inhibitors Marketing Authorization 2019-2021
Telmisartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2019-2021
Tigecycline J01AA Tetracyclines Marketing Authorization 2019-2021
Trastuzumab L01XC Monoclonal antibodies Marketing Authorization 2019-2021
Adalimumab L04AB Tumor necrosis factor alpha (TNFα) inhibitors Phase III CT 2019-2021
Donepezil N06DA Cholinesterase inhibitors Bioequivalence CT 2019-2021
Abiraterone L02BX Other hormone antagonists and related agents Marketing Authorization 2019-2021
Amlodipine C08CA Dihydropyridine Derivatives Marketing Authorization 2019-2021
Amlodipine C08CA Dihydropyridine Derivatives Рharmacovigilance Present
Atracurium besylate M03AC Other Quaternary Ammonium Compounds Рharmacovigilance Present
Bleomycin L01DC Other Cytotoxic Antibiotics Marketing Authorization 2019-2021
Bromhexine + Guaifenesin + Salbutamol R05C Expectorants,Excl Combinations With Cough Suppr. Marketing Authorization 2019-2021
Carbamazepine N03AF Carboxamide Derivatives Рharmacovigilance Present
Carboplatin L01XA Platinum Compounds Marketing Authorization 2019-2021
Celecoxib M01AH Coxibs Рharmacovigilance Present
Cisplatin L01XA Platinum Compounds Рharmacovigilance Present
Cyclophosphamide L01AA Nitrogen Mustard Analogues Marketing Authorization 2019-2021
Docetaxel L01CD Taxanes Рharmacovigilance Present
Docetaxel L01CD Taxanes Marketing Authorization 2019-2021
Donepezil N06DA Cholinesterase inhibitors Marketing Authorization 2019-2021
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Рharmacovigilance Present
Enoxaparin B01AB Heparin Group Marketing Authorization 2019-2021
Epirubicin L01DB Anthracyclines and Related Substances Рharmacovigilance Present
Ferric (III) hydroxide sacharose complex B03AC Iron, Parenteral Preparations Рharmacovigilance Present
Gemcitabine L01BC Pyrimidine Analogues Рharmacovigilance Present
Imipenem + Cilastatin J01DH Carbapenems Рharmacovigilance Present
Isoniazid J04AC Hydrazides Рharmacovigilance Present
Loratadine R06AX Other Antihistamines for systemic use Рharmacovigilance Present
Meropenem J01DH Carbapenems Marketing Authorization 2019-2021
Moxifloxacin J01MA Fluoroquinolones Рharmacovigilance Present
Original drug G01BA Antibiotics and Corticosteroids Phase III CT 2019-2021
Original drug G01BA Antibiotics and Corticosteroids Marketing Authorization 2019-2021
Original drug J05AX Other Antivirals Marketing Authorization 2019-2021
Ornidazole J01XD Imidazole Derivatives Рharmacovigilance Present
Paracetamol N02B Other Analgesics and Antipyretics Рharmacovigilance Present
Pregabalin N03AX Other Antiepileptics Рharmacovigilance Present
Pyrazinamide J04AK Other Drugs For Treatment Of Tuberculosis Рharmacovigilance Present
Temozolomide L01AX Other Alkylating Agents Рharmacovigilance Present
Acetylcysteine + Ambroxol R05CB Mucolytics Phase III CT 2019-2021
Agomelatine N06AX Other Antidepressants Bioequivalence CT 2019-2021
Ambroxol + Salbutamol + Guaifenesin R05C Expectorants,Excl Combinations With Cough Suppr. Phase III CT 2019-2021
Cefepime + Sulbactam J01DE Fourth-generation cephalosporins Phase III CT 2019-2021
Ethylmethylhydroxypyridine succinate N07XX Other Nervous System Drugs Phase III CT 2019-2021
Olmesartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2019-2021
Lysocime + Pyridoxine R02AA Antiseptics Phase III CT 2019-2021
Pregabalin N03AX Other Antiepileptics Bioequivalence CT 2019-2021
Rosuvastatin C10AA HMG CoA Reductase Inhibitors Bioequivalence CT 2019-2021
Telmisartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2019-2021
Ursodeoxycholic acid A05AA Bile Acid Preparations Bioequivalence CT 2019-2021
Chlormadinone + Ethinyl Estradiol G03AA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2019-2021
Ketolorac M01AB Acetic Acid Derivatives and Related Substances Phase III CT 2019-2021
Hydrocortisone acetate + Metronidazole + Natamycin + Chloramphenicol G01BA Antibiotics and Corticosteroids Phase III CT 2019-2021
Abacavir + Lamivudine + Zidovudine Antivirals for treatment of HIV infections, combination Bioequivalence CT 2016-2018
Amoxicillin + Clavulanic acid A07EC Aminosalicylic Acid and Similar Agents Marketing Authorization 2016-2018
Atazanavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Atazanavir J05AE HIV-proteinase inhibitors Marketing Authorization 2016-2018
Bendamustine L01AA Nitrogen Mustard Analogues Marketing Authorization 2016-2018
Cefepime + Sulbactam J01DE Fourth-generation cephalosporins Marketing Authorization 2016-2018
Ceftriaxone J01DD Third-generation cephalosporins Marketing Authorization 2016-2018
Chlorambucil L01AA Nitrogen Mustard Analogues Marketing Authorization 2016-2018
Ciprofloxacin J01MA Fluoroquinolones PVG Present
Cisplatin L01XA Platinum Compounds Marketing Authorization 2016-2018
Dasatinib L01XE Ингибиторы протеинкиназы Marketing Authorization 2016-2018
Doripenem J01DH Carbapenems Marketing Authorization 2016-2018
Doxorubicin L01DB Anthracyclines and Related Substances Marketing Authorization 2016-2018
Etoposide L01CB Podophyllotoxin Derivatives Marketing Authorization 2016-2018
Etoricoxib M01AH Coxibs Bioequivalence CT 2016-2018
Etoricoxib M01AH Coxibs Marketing Authorization 2016-2018
Fingolimod L04AA Selective Immunosuppressive Agents Bioequivalence CT 2016-2018
Fluorouracil L01BC Pyrimidine Analogues Marketing Authorization 2016-2018
Flutamide L02BB Anti-Androgens Marketing Authorization 2016-2018
Ganciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2016-2018
Hydroxycarbamide L01XX Other Antineoplastic Agents Marketing Authorization 2016-2018
Ibrutinib L01XE Ингибиторы протеинкиназы Bioequivalence CT 2016-2018
Ketorolac trometamol M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Phase III CT 2016-2018
Lapatinib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Lenalidomide L04AX Other Immunosuppressive Agents Marketing Authorization 2016-2018
Methotrexate L01BA Folic Acid Analogues Marketing Authorization 2016-2018
Metronidazole J01XD Imidazole Derivatives PVG Present
Nifuroxazide A07AX Other Intestinal Antiinfectives Marketing Authorization 2016-2018
Nilotinib L01XE Protein kinase inhibitors Marketing Authorization 2016-2018
Original drug B01AC Platelet Aggregation Inhibitors Excl. Marketing Authorization 2016-2018
Pantoprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2016-2018
Pazopanib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Saquinavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Sofosbuvir J05AP Antivirals for treatment of HCV infections Bioequivalence CT 2016-2018
Tamoxifen L02BA Anti-Estrogens Marketing Authorization 2016-2018
Telmisartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2016-2018
Abacavir + Lamivudine J05AR Antivirals for treatment of HIV infections, combination Marketing Authorization 2016-2018
Abiraterone L02BX Other hormone antagonists and related agents Bioequivalence CT 2016-2018
Abiraterone L02BX Other hormone antagonists and related agents Marketing Authorization 2016-2018
Albendazole P02CA Benzimidazole Derivatives Bioequivalence CT 2016-2018
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2016-2018
Bosentan C02KX Antihypertensives for pulmonary arterial hypertension Bioequivalence CT 2016-2018
Capecitabine L01BC Pyrimidine Analogues Bioequivalence CT 2016-2018
Celecoxib M01AH Coxibs Bioequivalence CT 2016-2018
Cisplatin L01XA Platinum Compounds Marketing Authorization 2016-2018
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin Marketing Authorization 2016-2018
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin Bioequivalence CT 2016-2018
Cycloserine J04A Drugs For Treatment Of Tuberculosis Bioequivalence CT 2016-2018
Darunavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Diclofenac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids PVG Present
Dorzolamide S01EC Carbonic Anhydrase Inhibitors Marketing Authorization 2016-2018
Entecavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2016-2018
Esomeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2016-2018
Etoricoxib M01AH Coxibs Bioequivalence CT 2016-2018
Etoricoxib M01AH Coxibs Marketing Authorization 2016-2018
Ferric (III) hydroxide sacharose complex B03AC Iron, Parenteral Preparations Marketing Authorization 2016-2018
Gefitinib L01XX Other Antineoplastic Agents Bioequivalence CT 2016-2018
Iohexol V08AB Watersol.,Nephrotropic, Low Osm. X-Ray Contr.Media Marketing Authorization 2016-2018
Lamivudine J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2016-2018
Meloxicam M01AC Oxicams Marketing Authorization 2016-2018
Montelukast R03DC Leukotriene receptor antagonists Marketing Authorization 2016-2018
Mycophenolic acid L04AA Selective Immunosuppressive Agents Bioequivalence CT 2016-2018
Nitrofurantoin J01XE Nitrofuran derivatives Marketing Authorization 2016-2018
Ofloxacin J01MA Fluoroquinolones Marketing Authorization 2016-2018
Original drug J01DD Third-generation cephalosporins Marketing Authorization 2016-2018
Paracetamol + Phenylephrine + Chlorphenamine maleate N02B Other Analgesics and Antipyretics Bioequivalence CT 2016-2018
Quetiapine N05AH Diazepines and oxazepines Bioequivalence CT 2016-2018
Ritonavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2016-2018
Rosuvastatin C10AA HMG CoA Reductase Inhibitors Marketing Authorization 2016-2018
Solifenacin G04BD Urinary Antispasmodics Bioequivalence CT 2016-2018
Sorafenib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2016-2018
Torasemide C03CA Sulfonamides, Plain Marketing Authorization 2016-2018
Tranexamic acid B02AA Amino Acids Marketing Authorization 2016-2018
Cefepime J01DE Fourth-generation cephalosporins Marketing Authorization 2016-2018
Cinacalcet H05BX Other anti-parathyroid agents Marketing Authorization 2016-2018
Docetaxel L01CD Taxanes Phase III CT 2016-2018
Efavirenz + Emtricitabine + Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2016-2018
Entecavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2016-2018
Imatinib L01XE Ингибиторы протеинкиназы Marketing Authorization 2016-2018
Imatinib L01XE Ингибиторы протеинкиназы Bioequivalence CT 2016-2018
Irbesartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2016-2018
Lenalidomide L04AX Other Immunosuppressive Agents Bioequivalence CT 2016-2018
Levocetirizine R06AE Piperazine Derivatives Marketing Authorization 2016-2018
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2016-2018
Levofloxacin J01MA Fluoroquinolones Bioequivalence CT 2016-2018
Linezolid J01XX Other Antibacterials Marketing Authorization 2016-2018
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2016-2018
Nilotinib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Original drug B01AC Platelet Aggregation Inhibitors Excl. Phase III CT 2016-2018
Original drug J01DD Third-generation cephalosporins Phase III CT 2016-2018
Oseltamivir J05AH Combinations Of Antibacterials Bioequivalence CT 2016-2018
Peginterferon alfa-2b L03AB Interferons Marketing Authorization 2016-2018
Pregabalin N03AX Other Antiepileptics Marketing Authorization 2016-2018
Rosuvastatin C10AA HMG CoA Reductase Inhibitors Bioequivalence CT 2016-2018
Sildenafil G04BE Drugs used in erectile dysfunction Marketing Authorization 2016-2018
Sildenafil G04BE Drugs used in erectile dysfunction Bioequivalence CT 2016-2018
Sunitinib L01XE Protein kinase inhibitors Bioequivalence CT 2016-2018
Tacrolimus L04AD Calcineurin inhibitors Marketing Authorization 2016-2018
Temozolomide L01AX Other Alkylating Agents Bioequivalence CT 2016-2018
Tenofovir + Emtricitabine J05AR Antivirals for treatment of HIV infections, combination Marketing Authorization 2016-2018
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2016-2018
Tramadol N02AX Other Opioids Marketing Authorization 2016-2018
Valganciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2016-2018
Vancomycin J01XA Glycopeptide Antibacterials Marketing Authorization 2016-2018
Abacavir + Lamivudine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Bioequivalence CT 2013-2015
Amoxicillin + Clavulanic acid A07EC Aminosalicylic Acid and Similar Agents Bioequivalence CT 2013-2015
Ceftriaxone + Sulbactam J01DD Third-generation cephalosporins Phase III CT 2013-2015
Celecoxib M01AH Coxibs Bioequivalence CT 2013-2015
Cinacalcet H05BX Other anti-parathyroid agents Bioequivalence CT 2013-2015
Ciprofloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Dienogest + Ethinylestradiol G03FA Progestogens and Estrogens, Fixed Combinations Bioequivalence CT 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Efavirenz + Emtricitabine + Tenofovir J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Erlotinib L01XE Protein kinase inhibitors Marketing Authorization 2013-2015
Erlotinib L01XE Protein kinase inhibitors Bioequivalence CT 2013-2015
Famciclovir J05AB Nucleosides and nucleotides Marketing Authorization 2013-2015
Irbesartan C09CA Angiotensin II Antagonists, Plain Bioequivalence CT 2013-2015
Ivabradine C01EB Other Cardiac Preparations Marketing Authorization 2013-2015
Ivabradine C01EB Other Cardiac Preparations Bioequivalence CT 2013-2015
Latanoprost S01EE Prostaglandin analogues Phase III CT 2013-2015
Levofloxacin J01MA Fluoroquinolones Bioequivalence CT 2013-2015
Linezolid J01XX Other Antibacterials Marketing Authorization 2013-2015
Linezolid J01XX Other Antibacterials Bioequivalence CT 2013-2015
Linezolid J01XX Other Antibacterials Phase III CT 2013-2015
Losartan + Hydrochlorothiazide C09DA Angiotensin II Antagonists and Diuretics Marketing Authorization 2013-2015
Meropenem J01DH Carbapenems Marketing Authorization 2013-2015
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Nevirapine J05AG Non-nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Pimecrolimus D11AH Agents for atopic dermatitis, excluding corticosteroids Phase III CT 2013-2015
Pregabalin N03AX Other Antiepileptics Bioequivalence CT 2013-2015
Rabeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2013-2015
Rabeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2013-2015
Stavudine J05AF Nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Tenofovir + Emtricitabine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Terizidone + Pyridoxine J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2013-2015
Timolol S01ED Beta Blocking Agents Marketing Authorization 2013-2015
Topiramate N03AX Other Antiepileptics Marketing Authorization 2013-2015
Travoprost S01EE Prostaglandin analogues Phase III CT 2013-2015
Valaciclovir J05AB Nucleosides and nucleotides Bioequivalence CT 2013-2015
Valganciclovir J05AB Nucleosides and nucleotides Bioequivalence CT 2013-2015
Valsartan C09CA Angiotensin II Antagonists, Plain Marketing Authorization 2013-2015
Abacavir J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2013-2015
Atracurium besilate M03AC Other Quaternary Ammonium Compounds Marketing Authorization 2013-2015
Darunavir J05AE HIV-proteinase inhibitors Marketing Authorization 2013-2015
Docetaxel L01CD Taxanes Marketing Authorization 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Famciclovir J05AB Nucleosides and nucleotides Bioequivalence CT 2013-2015
Imatinib L01XE Ингибиторы протеинкиназы Marketing Authorization 2013-2015
Imipenem + Cilastatin J01DH Carbapenems Marketing Authorization 2013-2015
Lamivudine + Zidovudine J05AR Antivirals for treatment of HIV infections, combination Marketing Authorization 2013-2015
Levocetirizine R06AE Piperazine Derivatives Bioequivalence CT 2013-2015
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Menotropins G03GA Gonadotrophins Marketing Authorization 2013-2015
Meropenem J01DH Carbapenems Marketing Authorization 2013-2015
Mesalazine A07EC Aminosalicylic Acid and Similar Agents Marketing Authorization 2013-2015
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Moxifloxacin J01MA Fluoroquinolones Phase III CT 2013-2015
Natural phospholipids R07AA Lung Surfactants Marketing Authorization 2013-2015
Ofloxacin J01MA Fluoroquinolones Marketing Authorization 2013-2015
Paracetamol N02B Other Analgesics and Antipyretics Phase III CT 2013-2015
Peginterferon L03AB Interferons Phase III CT 2013-2015
Rabeprazole A02BC Proton Pump Inhibitors Bioequivalence CT 2013-2015
Sulodexide B01AB Heparin Group Phase III CT 2013-2015
Teicoplanin J01XA Glycopeptide Antibacterials Phase III CT 2013-2015
Terizidone + Pyridoxine J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Tobramycin J01GB Other Aminoglycosides Phase III CT 2013-2015
Torasemide C03CA Sulfonamides, Plain Bioequivalence CT 2013-2015
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2013-2015
Citalopram N06AB Serotonin Reuptake Inhibitors Selective Marketing Authorization 2013-2015
Clopidogrel B01AC Platelet Aggregation Inhibitors Excl. Heparin Marketing Authorization 2013-2015
Cycloserine J04A Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Cycloserine + Pyridoxine J04A Drugs For Treatment Of Tuberculosis Bioequivalence CT 2013-2015
Cyproterone + Ethinylestradiol G03HB Antiandrogens and Estrogens Marketing Authorization 2013-2015
Darunavir J05AE HIV-proteinase inhibitors Bioequivalence CT 2013-2015
Efavirenz J05AG Non-nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Gabapentin N03AX Other Antiepileptics Marketing Authorization 2013-2015
Heparin B01AB Heparin Group Marketing Authorization 2013-2015
Ketorolac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Marketing Authorization 2013-2015
Lamivudine J05AF Nucleoside reverse transcriptase inhibitors Marketing Authorization 2013-2015
Lamivudine J05AF Nucleoside reverse transcriptase inhibitors Bioequivalence CT 2013-2015
Levofloxacin J01MA Fluoroquinolones Bioequivalence CT 2013-2015
Moxifloxacin J01MA Fluoroquinolones Bioequivalence CT 2013-2015
Nimesulide M01AX Other Antiinfl./Antirheumatic Agents, Non-Steroids Marketing Authorization 2013-2015
Sildenafil G04BE Drugs used in erectile dysfunction Bioequivalence CT 2013-2015
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2013-2015
Topiramate N03AX Other Antiepileptics Marketing Authorization 2013-2015
Urofollitropin G03GA Gonadotrophins Marketing Authorization 2013-2015
Zidovudine + Lamivudine J05AR Antivirals for treatment of HIV infections, combination Bioequivalence CT 2013-2015
Anastrozole L02BG Enzyme Inhibitors Marketing Authorization 2010-2012
Bisoprolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Clarithromycin J01FA Macrolides Marketing Authorization 2010-2012
Glucosamine + Chondroitin sulfate Potassium Adipate + Vitamin E M09AX Other Drugs For Disord. Of The Musc.-Skeletal Syst Marketing Authorization 2010-2012
Isoniazid + Pyrazinamide + Rifampicin J04AM Comb. Of Drugs For Treatment Of Tuberculosis Marketing Authorization 2010-2012
Letrozole L02BG Enzyme Inhibitors Marketing Authorization 2010-2012
Levetiracetam N03AX Other Antiepileptics Marketing Authorization 2010-2012
Moxifloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Mycophenolate mofetil L04AA Selective Immunosuppressive Agents Marketing Authorization 2010-2012
Nebivolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Paracetamol N02B Other Analgesics and Antipyretics Marketing Authorization 2010-2012
Piperacillin + Tazobactam J01CR Piperacillin and Enzyme Inhibitor Marketing Authorization 2010-2012
Rebamipide A02BX Other Drugs For Treatment Of Peptic Ulcer Marketing Authorization 2010-2012
Tacrolimus L04AD Calcineurin inhibitors Marketing Authorization 2010-2012
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Marketing Authorization 2010-2012
Terizidone J04AK Other Drugs For Treatment Of Tuberculosis Bioequivalence CT 2010-2012
Aminosalicylic acid J04AA Aminosalicylic Acid and Derivatives Marketing Authorization 2010-2012
Amoxicillin + Clavulanic acid A07EC Aminosalicylic Acid and Similar Agents Marketing Authorization 2010-2012
Bisoprolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Capreomycin J04AB Antibiotics Marketing Authorization 2010-2012
Cycloserine J04A Drugs For Treatment Of Tuberculosis Marketing Authorization 2010-2012
Diclofenac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Marketing Authorization 2010-2012
Drotaverine A03AD Papaverine and Derivatives Marketing Authorization 2010-2012
Epirubicin L01DB Anthracyclines and Related Substances Marketing Authorization 2010-2012
Hydrochlorothiazide + Losartan C09DA Angiotensin II Antagonists and Diuretics Marketing Authorization 2010-2012
Indapamide C03BA Sulfonamides, Plain Marketing Authorization 2010-2012
Ketorolac M01A Antiinflammatory/Antirheumatic Prod.,Non-Steroids Marketing Authorization 2010-2012
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Meropenem J01DH Carbapenems Marketing Authorization 2010-2012
Metamizole sodium + Pitofenone + Fenpiverinium bromide N02B Other Analgesics and Antipyretics Marketing Authorization 2010-2012
Nebivolol C07AB Beta Blocking Agents, Selective Marketing Authorization 2010-2012
Ornidazole J01XD Imidazole Derivatives Marketing Authorization 2010-2012
Rabeprazole A02BC Proton Pump Inhibitors Marketing Authorization 2010-2012
Gemcitabine L01BC Pyrimidine Analogues Marketing Authorization 2010-2012
Levofloxacin J01MA Fluoroquinolones Marketing Authorization 2010-2012
Temozolomide L01AX Other Alkylating Agents Marketing Authorization 2010-2012
Alglucosidase alfa A16AB Enzymes User testing of leaflet 2019-2021
Bortezomib L01XX Other Antineoplastic Agents User testing of leaflet 2019-2021
Oxaliplatin L01XA Platinum Compounds User testing of leaflet 2019-2021
Abacavir J05AF Nucleoside reverse transcriptase inhibitors User testing of leaflet 2019-2021
Levonorgestrel G03AC 3-Oxoandrosten (4) Derivatives User testing of leaflet 2019-2021
Cyproterone G03HA Antiandrogens, Plain Preparations User testing of leaflet 2019-2021
Darunavir J05AE HIV-proteinase inhibitors User testing of leaflet 2019-2021
Mycophenolic acid L04AA Selective Immunosuppressive Agents User testing of leaflet 2019-2021
Cyproterone G03HA Antiandrogens, Plain Preparations User testing of leaflet 2019-2021
Decitabine L01BC Pyrimidine Analogues User testing of leaflet 2019-2021
Mycophenolate mofetil L04AA Selective Immunosuppressive Agents User testing of leaflet 2019-2021
Insulin glargine + Lixisenatide A10AE Insulins and analogues, long-acting User testing of leaflet 2019-2021
Darunavir J05AE HIV-proteinase inhibitors User testing of leaflet 2019-2021
Aceclofenac M01AB Acetic Acid Derivatives and Related Substances User testing of leaflet 2019-2021
Hydrochlorothiazidum + Telmisartan C09DA Angiotensin II Antagonists and Diuretics User testing of leaflet 2019-2021
Lenalidomide L04AX Other Immunosuppressive Agents User testing of leaflet 2019-2021
Etoricoxib M01AH Coxibs User testing of leaflet 2019-2021
Telmisartan + Amlodipin C09DB Антагонисты ангиотензина II в комбинации с блокаторами кальциевых каналов User testing of leaflet 2019-2021
Rosuvastatin + Valsartan C10BX HMG CoA reductase inhibitors, other combinations User testing of leaflet 2019-2021
Drugs for treatment of hyperkalemia and hyperphosphatemia V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia User testing of leaflet 2019-2021
Influenza Vaccines J07B Influenza Vaccines User testing of leaflet 2019-2021
Doxylamine R06AA Aminoalkyl Ethers User testing of leaflet 2019-2021
Telmisartan C09CA Angiotensin II Antagonists, Plain User testing of leaflet 2019-2021
Poliomyelitis Vaccines J07BF Poliomyelitis Vaccines User testing of leaflet 2019-2021
Algeldrate A02A Antacids User testing of leaflet 2019-2021
Fulvestrant L02BA Anti-Estrogens User testing of leaflet 2019-2021
Carvedilol C07AG Alpha and Beta Blocking Agents User testing of leaflet 2019-2021
Nifedipine C08CA Dihydropyridine Derivatives User testing of leaflet 2019-2021
Azithromycin J01FA Macrolides User testing of leaflet 2019-2021
Azithromycin J01FA Macrolides User testing of leaflet 2019-2021
Ciprofloxacin J01MA Fluoroquinolones User testing of leaflet 2019-2021
Lenvatinib L01XE Ингибиторы протеинкиназы User testing of leaflet 2019-2021

CONTACTS

Russia, Moscow.

Multifanctional complex «Federation»
Presnenskaya embankment, 12
East Tower, 27th floor, 17 room.

Phone:   + 7 (495) 374-62-84

E-mail: info@pharmrussia.com

Social network:

© ARS PHARMRUSSIA: CLINICAL & REGULATORY EXPERT CRO, 2009-2020
All rights reserved.